Year: 2024

BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. “We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), in Barcelona, Spain. The patients were enrolled in the biomarker-enriched, Cohort 8 of the study and were preselected for CDKN2A and/or CDKN2B abnormalities,” said Spiro Rombotis,...

Monthly Active Users Reached Approximately 76.9 million for the QuarterRecord Global Net Additions to Paying Circles of 159 thousand – Reaching Nearly 2.2 million TotalTotal Revenue Grew 18% Year-Over-Year to $92.9 million Annualized Monthly Revenue increased 30% Year-Over-Year to $336.2 millionRaising Outlook for 2024 Adjusted EBITDA SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) — San Francisco area-based Life360, Inc. (Life360 or the Company) (NASDAQ: LIF) (ASX: 360) today reported unaudited financial results for the quarter ended September 30, 2024. The Company built on momentum from the previous quarter and again achieved record quarterly results in Monthly Active Users (“MAUs”), Paying Circles, Subscription Revenue, and Annualized Monthly Revenue. “Life360 made tremendous progress in Q3 2024, achieving our best-ever...

BEDFORD, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) — Legacy Housing Corporation (“Legacy” or the “Company,” NASDAQ: LEGH) today announced its financial results for the third quarter ended September 30, 2024. Financial HighlightsNet revenue for the third quarter of 2024 was $44.3 million, a decrease of 11.4% from the third quarter of 2023. Income from operations for the third quarter of 2024 was $15.3 million, a decrease of 19.4% from the third quarter of 2023. Net income for the third quarter of 2024 was $15.8 million, a decrease of 1.8% from the third quarter of 2023. Basic earnings per share for the third quarter of 2024 was $0.65, a decrease of 1.5% from the third quarter of 2023. Book value for the third quarter of 2024 was $479.3 million, an increase of 11.6% from the third quarter of 2023. Book value per share1 for the third...

WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Directors has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a control Closed private placement for net proceeds of $11.6 Million in October 2024 extending cash runway through 2025NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) —  IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today reported financial results for the third quarter ended September 30, 2024, and...

/NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE U.S./ TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Urbana Corporation (TSX & CSE: URB & URB.A) Urbana Corporation announces today that it has filed its unaudited interim Financial Statements and Management’s Discussion and Analysis for the nine-month period ended September 30, 2024 with the applicable Canadian securities regulators. PDF versions of the documents are available at www.urbanacorp.com and at www.sedarplus.ca. For further information contact: Elizabeth Naumovski Investor Relations (416) 595-9106 enaumovski@urbanacorp.com . 150 KING ST. W., SUITE 1702, TORONTO, ONTARIO M5H 1J9   TEL: 416-595-9106 FAX: 416-862-2498 www.urbanacorp.com